Investor Relations

Investor FAQs

 

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revance's science is based upon a proprietary peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator.

The company started operations in 2002 and began trading as public company in February of 2014. Today the company employs more than 106 staff members and as of December 31, 2016, had approximately $185 million in cash and investments to fund operations into the fourth quarter of 2018. Revance's headquarters is located in Newark, California, occupying approximately 90,000 square feet of office, laboratory and manufacturing space.

Revance Therapeutics trades on the The NASDAQ Global Market under the ticker symbol “RVNC”.

Revance Therapeutics began trading as public company on February 6, 2014 (NAS:RVNC). A total of 6,900,000 shares (including the underwriters’ overallotment of 900,000 shares) were offered at $16 per share.

The company completed a follow-on offering in June 2014 and issued an additional 4.6 million common shares (including the underwriters' exercised option for 600,000 shares) at $30.50 per share.

In November of 2015, the company completed an additional public offering of 3.7 million shares of its common stock (including the underwriters exercise option for 487,500 shares) at $36.00 per share.

The Company’s headquarters is located in Newark, California.  Our principal offices are located at 7555 Gateway Boulevard Newark, California 94560.  The phone number is (510) 742-3400.

The biographies of Revance Therapeutics’ directors are available in the “Board of Directors” section of our company website:http://www.revance.com/company/index.php#board_of_directors

The biographies of Revance Therapeutics’ management are available in the “Management Team” section of our company website:http://www.revance.com/company/index.php#management_team

As of February 24, 2017, Revance Therapeutics had a total common shares outstanding of 24.3 million.

As of February 7, 2017, Revance Therapeutics held approximately 183 issued patents and approximately 134 pending patent applications in several countries.

Revance Therapeutics’ fiscal year ends December 31st.

Revance Therapeutics’ independent auditor is PricewaterhouseCoopers LLP.

Address: 488 S Almaden Blvd
#1800, San Jose, California, 95110
Phone: (408) 817-3700

Revance Therapeutics’ outside legal counsel is Cooley LLP.

Address: 3175 Hanover Street Palo Alto, California, 94304

Phone: (650) 843-5000

No, Revance Therapeutics does not pay a dividend at this time.

No, Revance Therapeutics does not offer a direct stock purchase program.

Revance Therapeutics’ quarterly and annual reports and other SEC filings are available by selecting the “Financial Information” section of our “Investors” page on our website (http://investors.revance.com/sec.cfm), or through SEC’s website (www.sec.gov).

Revance will hold its 2017 Annual Meeting of Stockholders on May 11, 2017 at 8:00am PDT. 

Computershare
USA
+1 (877) 373 6374
(US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)
web.queries@computershare.com

Shareholder Correspondence should be mailed to:
Computershare
P.O. Box 505000
Louisville, KY  40233

Shareholder Overnight correspondence should be sent to:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202

Please see the "Events & Presentations" section of our website for a listing of upcoming earnings announcements and other key events. http://investors.revance.com/events.cfm
 

You can contact Revance Therapeutics’ Investor Relations via email by clicking here (http://investors.revance.com/contactus.cfm).

The Company was incorporated in the state of Delaware in August 1999 under the name Essentia Biosystems, Inc.  It commenced operations in June 2002 and, in April 2005, changed its name to Revance Therapeutics, Inc.

If your shares are held in street name (by your broker), you must notify the securities firm holding your stock.  If you hold stock certificates in your own name, address changes should be submitted in writing via U.S. mail to our transfer agent, Computershare:

For written requests by regular mail:
Computershare
P.O. Box 30170
College Station, TX, 77842
USA

For written requests by overnight delivery:
Computershare
211 Quality Circle, Suite 210
College Station, TX, 77845
USA

If you hold stock certificates in your own name, please contact our transfer agent, Computershare, regarding the replacement of lost certificates:

For telephone inquiries:
+1 (877) 373 6374 (US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)

 

For requests by email:
web.queries@computershare.com

For written requests by regular mail:
Computershare
P.O. Box 30170
College Station, TX, 77842
USA

For written requests by overnight delivery:
Computershare
211 Quality Circle, Suite 210
College Station, TX, 77845
USA

As of December 31, 2016, Revance Therapeutics had 106 full-time employees.

Russell 2000 and 3000
NASDAQ Biotechnology Index
NASDAQ Health Care
NASDAQ Composite
NASDAQ Global Market Composite
Nasdaq US Small Cap Growth Inde
Nasdaq US Small Cap Growth NTR
NASDAQ Composite Total Return
Settle - NASDAQ Composite

Please submit your question using the form below.

* Indicates required field
Shareholder Tools